Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05363891 · ClinicalTrials.gov registry record · Phase 2
Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis
A Phase 2 study, sponsored by XBiotech.
- Completed
- Registry status
- Phase 2
- Development phase
- 243
- Enrollment target
NCT05363891 is a Phase 2 study that has completed, run by XBiotech. The registered enrollment target is 243 participants.
The verdict
NCT05363891, a Phase 2 study, has completed, sponsored by XBiotech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 243 participants
- Enrollment target
Study Summary
Phase II, Double-Blind, Placebo-Controlled, Randomized Trial Examining Natrunix in Combination with MTX (+Folate) for the Treatment of Rheumatoid Arthritis
Interventions
- DRUG Placebo
- DRUG Natrunix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2023-08-08 |
| Est. Completion | 2024-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05363891
The ClinicalTrials.gov registry entry for NCT05363891 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 243 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is XBiotech, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05363891 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05363891 about?
NCT05363891 is a clinical study titled "Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis". Phase II, Double-Blind, Placebo-Controlled, Randomized Trial Examining Natrunix in Combination with MTX (+Folate) for the Treatment of Rheumatoid Arthritis
What is the current status of trial NCT05363891?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 243 participants. The study started on 2023-08-08. Estimated completion is 2024-10-31.
What interventions are being tested in trial NCT05363891?
The interventions under investigation include: Placebo (DRUG), Natrunix (DRUG).
Who is sponsoring clinical trial NCT05363891?
This trial is sponsored by XBiotech, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.